Media stories about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4351517514734 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Aerie Pharmaceuticals Inc (AERI) Technicals Are Speaking Volumes; Where is This Stock Headed? – Evergreen Caller (evergreencaller.com)
- Here is why Technicals Are a BEAR on Aerie Pharmaceuticals, Inc. (AERI) – StockNewsGazette (stocknewsgazette.com)
- Aerie Pharmaceuticals, Inc. (AERI) registers a price change of 0.48% while LHC Group, Inc. (LHCG) finishes with a … – Stocks Gallery (stocksgallery.com)
- What’s Behind Aerie Pharmaceuticals Inc (AERI)’s Movement – Sparta Review (spartareview.com)
- See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. (finance.yahoo.com)
A number of research analysts have issued reports on the stock. HC Wainwright set a $69.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, April 15th. Aegis raised their price target on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $62.00 price target (up previously from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. BidaskClub raised shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Finally, Cowen and Company set a $100.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $66.08.
Aerie Pharmaceuticals (AERI) traded down 2.14% during mid-day trading on Friday, hitting $50.35. 476,944 shares of the stock were exchanged. The company has a 50 day moving average price of $54.55 and a 200 day moving average price of $48.00. The firm’s market cap is $1.83 billion. Aerie Pharmaceuticals has a 52-week low of $18.35 and a 52-week high of $59.50.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.02. On average, analysts anticipate that Aerie Pharmaceuticals will post ($2.56) EPS for the current year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 9.36% of the stock is owned by corporate insiders.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.